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Liver ﬁbrosis, or cirrhosis, is a common end-stage condition of many chronic liver diseases
after incomplete recovery from hepatocyte damage. During ﬁbrosis progression, hepa-
tocellular damage and inﬂammation trigger complex cellular events that result in collagen
deposition and the disruption of the normal liver architecture. Hepatic stellate cell activation
and transdifferentiation into myoﬁbroblasts are key events in liver ﬁbrogenesis. Research
ﬁndings from cell culture and animal models have revealed that the Janus kinase-signal
transducer and activator of transcription (Jak-STAT) signaling pathway, which can be acti-
vated by many cytokines, growth factors, and hormones, plays a critical role in hepatic
ﬁbrogenesis. This review summarizes the biological signiﬁcance of diverse cytokines and
their downstream signaling protein STATs in hepatic ﬁbrogenesis.
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INTRODUCTION
Liver ﬁbrosis, or scarring of the liver, is induced by various types
of chronic liver diseases and is a major cause of morbidity and
mortality worldwide. During ﬁbrosis progression, inﬂammation
and liver injury trigger complex cellular events that result in colla-
gen deposition and the disruption of the normal liver architecture.
Generally, following liver injury from any causes, hepatic stellate
cells (HSCs) undergo activation and transformation. HSCs are
considered the most important cell type for the production of
collagens (Friedman, 2008). Many other types of cells, such as
bone marrow-derived progenitor cells, portal ﬁbroblasts, cholan-
giocytes, and hepatocytes may also contribute to the production
of collagens to a lesser extent (Kaimori et al., 2007; Higashiyama
et al., 2009; Novo et al., 2009). In addition, immune cells may
regulate ﬁbrogenesis via the secretion of a wide variety of growth
factors and cytokines.
Many inﬂammatory cytokines have been shown to play key
roles in regulating liver ﬁbrogenesis (Bataller and Brenner, 2005;
Friedman, 2008). Following liver injury, many types of cells in the
liver, includingKupffer cells,hepatocytes,HSCs,natural killer cells,
lymphocytes, and dendritic cells, have been shown to produce pro-
inﬂammatory cytokines and hepatoprotective cytokines. Many of
these cytokines can activate the Janus kinase–signal transducer and
activator of transcription (JAK–STAT) signaling pathway in the
liver, including interleukin-6 (IL-6), interferon-γ (IFN-γ), IFN-
α/β, and IL-22 (Gao, 2005). Signaling through the JAK–STAT
pathway is initiated when an extracellular cytokine protein binds
to its corresponding transmembrane receptor complex. This leads
Abbreviations: CDE diet, choline-deﬁcient, ethionine-supplemented diet; DDC
diet, 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet; HSC, hepatic stellate cell; IL,
interleukin; JAK–STATs, Janus kinase–signal transducers and activators of tran-
scription; TGF-β, transforming growth factor-beta; TIMP-1, tissue inhibitor of
metalloproteinase 1.
to activation of the JAKs, including Jak1, 2, 3, and TYK2. The JAKs
mediate phosphorylation at speciﬁc receptor tyrosine residues,
which then serve as docking sites for the STATs (STAT1, 2, 3, 4, 5a,
5b, and 6). Studies from animal models have revealed that activa-
tionof the JAK–STATpathwayby an array of cytokines plays a vari-
ety of important functions in liver pathophysiology (Gao, 2005;
Mair et al., 2011;Wang et al., 2011a;Gao et al., 2012). In this review,
we update the biological signiﬁcance of cytokines and their down-
stream STAT signaling pathways in liver ﬁbrogenesis (Table 1).
STAT1: A NEGATIVE REGULATOR OF LIVER FIBROSIS
It is well established that STAT1-deﬁcient mice display increased
sensitivity to infection by microbial pathogens. Using STAT1-
deﬁcient mice, we have previously demonstrated that STAT1
negatively regulates liver ﬁbrosis through the inhibition of HSC
proliferation and the stimulation of NK cell killing of activated
HSCs (Jeong et al., 2006). Consistent with these ﬁndings, several
cytokines that activate the STAT1 signaling pathway have been
shown to inhibit liver ﬁbrosis.
IFNs/STAT1 IN LIVER FIBROSIS
STAT1 ismainly activated by IFN-α/β and IFN-γ in the liver. Treat-
ment with IFN-α has been shown to signiﬁcantly improve the
serum levels of ﬁbrotic markers and the degree of hepatic ﬁbro-
sis in mice. IFN-α directly suppresses collagen gene transcription
through the interaction of phosphorylated Stat1 and p300 (Ina-
gaki et al., 2003). IFN-β treatment reduces concanavalinA-induced
hepatic ﬁbrosis via the inhibition of transforming growth factor-
beta (TGF-β),basic ﬁbroblast growth factor, collagen type IA2,and
tissue inhibitor of metalloproteinase 1 (TIMP-1) mRNA expres-
sion (Tanabe et al., 2007). IFN-γ displays anti-ﬁbrotic effects in the
liver via the induction of STAT1 phosphorylation, the upregula-
tion of Smad7 expression, and the impairment of TGF-β signaling
(Weng et al., 2007).
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Table 1 | Functions of STATs in liver fibrogenesis.
STATs Cell types Target genes Major cellular effects on liver fibrogenesis
STAT1 HSCs Collagen↓TGF-β↓TIMP-1↓ Smad7↑ Fibroblast growth factor ↓ Anti-ﬁbrotic effects
NK cells TRAIL↑ NKG2D↑ Anti-ﬁbrotic effects
Hepatocytes IRF-1↑ p21↑ caspase-3↑ Liver injury, pro-ﬁbrotic effects
STAT2 Hepatocytes Unknown Unknown
STAT3 Hepatocytes Bcl-2↑ Bcl-xL↑ cyclin D↑ Hepatoprotection, anti-ﬁbrotic
Hepatocytes, HSCs TIMP-1↑ Pro-ﬁbrotic effects
STAT4 NK and NKT cells IFN-γ↑ Anti-ﬁbrotic effects
STAT5 Hepatocytes Insulin-like growth factor 1↑ Hepatoprotective genes↑ Hepatoprotection, anti-ﬁbrotic
STAT6 HSCs Fibrotic genes↑ Collagens↑ Pro-ﬁbrotic effects?
IL-27/STAT1 IN LIVER FIBROSIS
In addition to IFNs, IL-27 also induces STAT1 activation in the
liver. IL-27 belongs to the IL-6/IL-12 cytokine family and is
secreted by activated macrophages and dendritic cells. Treatment
with IL-27 activates STAT1 and, to a lesser extent, STAT3 in the
human HSC cell line LX2 and in primary rat HSCs (Schoenherr
et al., 2010), suggesting that IL-27 may inhibit liver ﬁbrosis. How-
ever, further studies are required to conﬁrm the anti-ﬁbrotic effects
of the IL-27/STAT1 pathway in vivo.
STAT2
STAT2 is exclusively activated by IFN-α, IFN-β, and IFN-λ
(Radaeva et al., 2002; Balagopal et al., 2010; Afdhal et al., 2011).
Treatment with IFN-α induces signiﬁcant STAT2 activation in pri-
mary human hepatocytes (Radaeva et al., 2002). The activation of
STAT2 likely plays a key role in the antiviral effects of IFN-α in
patients with viral hepatitis. Although the antiviral function of
STAT2 is well documented, the role of STAT2 in liver injury and
ﬁbrosis has not yet been explored.
STAT3
A variety of cytokines have been shown to induce STAT3 acti-
vation in the liver, playing key roles in inducing the acute-phase
response, protecting against hepatocellular damage, and promot-
ing liver regeneration (Wang et al., 2011a). However, the roles of
STAT3 in liver ﬁbrogenesis remain largely unknown. Hepatocyte-
speciﬁc STAT3 knockout mice displays a higher degree of liver
ﬁbrosis compared with wild-type mice in various models of liver
ﬁbrosis induced byCCl4 administration (Wang et al., 2011b), feed-
ing with a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet
(Plum et al., 2010), feeding with a choline-deﬁcient, ethionine-
supplemented (CDE) diet (Kroy et al., 2010), or upon deletion
of the multidrug resistance gene 2 (Mair et al., 2010). The obvi-
ous mechanism by which hepatocyte STAT3 protects against liver
ﬁbrosis is that hepatocyte STAT3 activation prevents hepatocellu-
lar damage and subsequently reduces injury-driven liver ﬁbroge-
nesis. A recent study suggests that activation of STAT3 in hepato-
cytes inhibits liver ﬁbrosis by stimulating hepatocytes to produce
unknown soluble factors that inhibit HSC activation (Shigekawa
et al., 2011). Further studies are needed to identify these soluble
factors.
Because HSC-speciﬁc STAT3 knockout mice are not available,
the role of HSC STAT3 in liver ﬁbrogenesis in vivo has not been
determined. Mice or rats deﬁcient in leptin or leptin signaling are
resistant to the development of liver ﬁbrosis (Honda et al., 2002;
Ikejima et al., 2002; Saxena et al., 2002), suggesting that leptin
may promote liver ﬁbrosis via the activation of STAT3 in HSCs
in vivo. In vitro experiments demonstrate that the inhibition of
JAK/STAT3 activation by the speciﬁc JAK2 inhibitor AG490 pre-
vents HSC early activation, which suggests that leptin activation
of STAT3 promotes HSC survival and activation (Lakner et al.,
2010). In addition, STAT3 is also involved in the leptin- and
IL-6-mediated production of TIMP-1 in HSCs and hepatocytes,
respectively (Cao et al., 2004; Wang et al., 2011c). TIMP-1 is a
survival factor for HSCs; thus, activation of STAT3 in HSCs and
hepatocytes may increase liver ﬁbrogenesis via the upregulation of
TIMP-1.
Until recently, the roles of STAT3 in other non-parenchymal
cells and inﬂammatory cells in liver ﬁbrogenesis remain largely
unclear. Recently,Wang et al. (2009) provided evidence suggesting
that leptin can promote TGF-β1 production in Kupffer cells via
the activation of STAT3 and consequently augment liver ﬁbrogen-
esis. This suggests that STAT3 activation in Kupffer cells by leptin
exacerbates liver ﬁbrosis. However, it is known that the activa-
tion of STAT3 by IL-10 in macrophages and Kupffer cells is a key
anti-inﬂammatory signal for the attenuation of liver inﬂamma-
tion (Horiguchi et al., 2008, 2010; Lafdil et al., 2009). Thus, the
activation of STAT3 by IL-10 in Kupffer cells and macrophages
may prevent liver inﬂammation and ﬁbrogenesis. Further studies
are needed to clarify the functions of STAT3 in Kupffer cells as well
as in other types of sinusoidal cells and inﬂammatory cells in the
pathogenesis of liver ﬁbrogenesis.
Clinical data have shown that STAT3–DNAbinding ismarkedly
suppressed in alcoholic and HCV ﬁbrotic patients when com-
pared with normal healthy livers, and ﬁbrosis progression in
HCV-infected patients is positively correlated with a continuous
decline in STAT3–DNA binding activity (Starkel et al., 2005, 2007),
indicating that STAT3 may also protect against liver ﬁbrosis in
patients.
In the liver, STAT3 is mainly activated by IL-6 and its related
cytokines leptin, and IL-22. The roles of these cytokines in liver
ﬁbrogenesis are discussed below.
IL-6/STAT3 IN LIVER FIBROSIS
IL-6 is a critical proregenerative factor and an acute-phase inducer
in the liver. IL-6 stimulates hepatocytes to produce a variety of
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acute-phase proteins, including C-reactive protein, complement
C3, and serum amyloid A (Ramadori and Christ, 1999). However,
numerous studies demonstrated the hepatoprotective role of IL-6
against liver injury in spite of its pro-inﬂammatory effect (Blind-
enbacher et al., 2003; Wuestefeld et al., 2003). With respect to
liver ﬁbrosis, there are some conﬂicting reports. First, IL-6 knock-
out mice are reported to be more susceptible to CCl4-induced liver
injury and ﬁbrosis (Kovalovich et al., 2000).Another study showed
that the lack of gp130/STAT3-mediated signaling in hepatocytes
resulted in enhanced chronic cholestatic liver injury and ﬁbro-
sis progression induced by DDC diet feeding (Plum et al., 2010).
Other studies have demonstrated that liver ﬁbrosis is reduced in IL-
6-deﬁcient mice after CCl4 treatment (Sun et al., 2004; Rio et al.,
2008). The reasons for the differences observed in these experi-
ments remain unclear. In vitro cell culture experiments showed
that Kupffer cell-derived IL-6 promotes HSC survival and prolif-
eration (Nieto, 2006). Clinical studies showed that hepatic IL-6
expression is upregulated and correlates positively with the degree
of liver ﬁbrosis in opisthorchiasis periductal ﬁbrosis and in non-
alcoholic steatohepatitis (Dogru et al., 2008; Wieckowska et al.,
2008; Sripa et al., 2009). Furthermore, genetic polymorphisms of
IL-6 are linked with ﬁbrosis progression in patients with chronic
HCV infection (Cussigh et al., 2011). Because IL-6 receptors are
expressed ubiquitously on all types of liver cells, it is plausi-
ble to speculate that IL-6 may positively and negatively regulate
liver ﬁbrosis by targeting different types of liver cells. For exam-
ple, IL-6 protects against hepatocellular damage, thereby reducing
injury-driven liver ﬁbrosis,while it may also directly promote HSC
survival and proliferation, followed by enhanced liver ﬁbrosis. The
ﬁnal effect of IL-6 on liver ﬁbrosis is likely determined by the
balance between these inhibitory and stimulatory effects and is
dependent on the stage and etiology of liver ﬁbrosis.
LEPTIN/STAT3 IN LIVER FIBROSIS
The critical role of leptin in inducing liver ﬁbrogenesis was ﬁrst
noticed from the ﬁndings that leptin-deﬁcient ob/ob mice and
leptin-receptor-deﬁcient Zucker rats are resistant to the develop-
ment of liver ﬁbrosis (Honda et al., 2002; Ikejima et al., 2002;
Saxena et al., 2002). A recent study showed that the administra-
tion of leptin increases thioacetamide-induced liver ﬁbrosis, while
the injection of mouse leptin antagonist attenuates it (Elinav et al.,
2009). In vitro treatment of primary rat HSCs with a leptin antag-
onist, either alone or with leptin, has been shown to suppress the
pro-ﬁbrotic effects of leptin (Elinav et al., 2009). Furthermore,
in vitro experiments with leptin have shown to induce STAT3
activation in HSCs, and the blockade of STAT3 activation dimin-
ishes leptin-mediated promotion of HSC survival and activation
(Lakner et al., 2010). Finally, STAT3 is also involved in the leptin-
mediated production of TIMP-1, an important survival factor for
HSCs (Cao et al., 2004). Collectively, the pro-ﬁbrotic effect of lep-
tin is likely mediated via the direct promotion of HSC survival
and proliferation or the indirect upregulation of TIMP-1, which
subsequently promotes HSC survival.
IL-22/STAT3 IN LIVER FIBROSIS
IL-22 has been shown to play an important role in protecting
against liver injury (Radaeva et al., 2004; Zenewicz et al., 2007;
Park et al., 2011), ameliorating fatty liver disease (Ki et al., 2010;
Yang et al., 2010), and promoting liver cancer development (Jiang
et al., 2011; Park et al., 2011). An in vitro study showed that IL-22
promotes liver cell regeneration by increasing hepatic cell prolif-
eration and hepatocyte migration through the activation of Akt
and STAT signaling, which is abrogated by SOCS-1/3 overexpres-
sion (Brand et al., 2007). Although the hepatoprotective effects of
IL-22 have been extensively studied, the effects of IL-22 on liver
ﬁbrogenesis have not been investigated.
STAT4
It is well documented that IL-12 and IFN-α/β can induce STAT4
activation in several types of immune cells and subsequently
generate inﬂammation during protective immune responses and
immune-mediated diseases (Kaplan, 2005). The activation of
STAT4 has not been reported in hepatocytes, and the functions of
STAT4 in liver injury and ﬁbrosis remain obscure. IL-12-deﬁcient
mice are resistant to autoimmune cholangitis in dominant nega-
tive TGF-β receptor type II mice (Yoshida et al., 2009) and to Con
A-induced T cell hepatitis (Zhu et al., 2007), while the overexpres-
sion of IL-12 in the liver induces liver injury (Rodriguez-Galan
et al., 2009). In addition, IL-12 treatment has been shown to induce
liver inﬂammation and inhibit liver tumor growth in several ani-
mal models (Harada et al., 2004; Chang et al., 2007), which is
likely mediated via IL-12 activation of NK and NKT cells and
the subsequent production of IFN-γ (Subleski et al., 2006). This
suggests that IL-12 acts as a pro-inﬂammatory cytokine to pro-
mote liver injury and ﬁbrosis likely via the activation of STAT4 in
immune cells. In contrast, a recent study has demonstrated that
IL-10−/− IL-12/23(p40)−/− IL-13Rα2−/− triple knockout mice
are more susceptible to S. mansoni-induced liver ﬁbrosis, por-
tal hypertension, hepatosplenomegaly, gastrointestinal bleeding,
ascites, thrombocytopenia, esophageal and gastric varices, anemia,
and increased levels of liver enzymes (Mentink-Kane et al., 2011),
suggesting that IL-10, IL-12p40, and IL-13Rα2 act cooperatively to
suppress liver ﬁbrosis in mice following infection with S. mansoni.
Collectively, IL-12 activation of STAT4 in immune cells induces
inﬂammation in the liver, which promotes liver injury and ﬁbro-
sis, but may also protect against infection, thereby ameliorating
liver injury and ﬁbrosis.
STAT5
The activation of STAT5 in hepatocytes is mainly induced by
growth hormone (GH) and other cytokines to a lesser extent.
Hepatocyte-speciﬁc STAT5 knockout mice were initially gener-
ated in Dr. Lothar Hennighausen’s laboratory (Cui et al., 2007).
Using this strain of knockout mice, they have demonstrated that
loss of STAT5 in hepatocytes results in elevated TGF-β levels and
enhancedGH-induced STAT3 activity in the liver after chronic car-
bon tetrachloride treatment, suggesting that STAT5 inhibits liver
ﬁbrogenesis via the downregulation of TGF-β and STAT3 (Hosui
et al., 2009; Baik et al., 2011). The anti-ﬁbrotic effect of STAT5
is also demonstrated in another murine model of liver ﬁbrosis
induced by deleting the multidrug resistance gene 2 (Blaas et al.,
2010). Deletion of both multidrug resistance gene 2 (global dele-
tion) and STAT5 (hepatocyte and cholangiocyte-speciﬁc deletion)
results in an early and severe liver ﬁbrosis phenotype, accompanied
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by reduced expression of important hepatoprotective genes, such
as epidermal growth factor receptor, hepatocyte nuclear factor 6,
prolactin receptor, and leukemia inhibitory factor receptor as well
as increasednumbers of apoptotic hepatocytes. Furthermore,dele-
tion of STAT5 in the liver promoted carbon tetrachloride-induced
hepatic tumorigenesis in wild-type mice (Hosui et al., 2009) and
induced spontaneous liver cancer development in liver-speciﬁc
glucocorticoid receptor knockout mice (Mueller et al., 2011) or
in GH transgenic mice (Friedbichler et al., 2012). The protective
effect of STAT5 on hepatic carcinogenesis is likely mediated via
the induction of a key cell cycle inhibitor–p15INK4B expression
in hepatocytes (Yu et al., 2010) and protection against fatty liver
disease and liver injury (Mueller et al., 2011; Friedbichler et al.,
2012).
Although the functions of hepatocyte STAT5 have been exten-
sively investigated, little is known about STAT5 activation in HSCs
and other non-parenchymal cells, and how STAT5 activation in
these cells affects the pathogenesis of liver ﬁbrogenesis remains
obscure.
STAT6
STAT6 is mainly activated by Th2 cytokines, including IL-4 and
IL-13. The roles of both IL-4 and IL-13 in liver ﬁbrosis have been
extensively investigated, especially in a model of S. mansoni infec-
tion (Barron and Wynn, 2011), while the functions of STAT6 in
liver ﬁbrogenesis remain obscure. Disruption of the IL-13 gene
or blockage of IL-13 with inhibitors leads to markedly reduced
liver ﬁbrosis after infection with S. mansoni (Chiaramonte et al.,
1999a, 2001; Fallon et al., 2000), indicating that IL-13 is a pro-
ﬁbrogenic cytokine during S. mansoni infection. Expression of
IL-13 is elevated and correlates with liver ﬁbrosis in some patients
with HBV or HCV infection. This suggests that IL-13 may also
contribute to the pathogenesis of liver ﬁbrosis in viral hepatitis
(Weng et al., 2009). The pro-ﬁbrogenic effect of IL-13 is likely
mediated via the upregulation of a wide variety of ﬁbrotic pro-
teins in HSCs and the induction of HSC activation (Chiaramonte
et al., 1999a;Weng et al., 2009). IL-13 may also regulate liver ﬁbro-
sis via the activation of macrophages, which plays an important
role in the induction and resolution of liver ﬁbrosis (Barron and
Wynn, 2011).
IL-4 is also considered a pro-ﬁbrotic cytokine because IL-4 can
directly stimulate HSC activation and the production of collagens
(Aoudjehane et al., 2008; Jin et al., 2011). The potency of IL-4
stimulation of HSC activation in vitro appears to be similar to that
of TGF-β (Aoudjehane et al., 2008). In addition, the expression
of IL-4 is upregulated in the ﬁbrotic liver of S. mansoni-infected
baboons (Farah et al., 2000), and blockage of IL-4 signiﬁcantly
reduces liver ﬁbrosis in S. mansoni-infected mice (Cheever et al.,
1994). However, several other studies suggest that although both
IL-4 and IL-13 are critical in the progression of the S. man-
soni-induced disease, IL-13, but not IL-4, plays a key role in S.
mansoni mediated granuloma formation and liver ﬁbrosis as the
reduction in ﬁbrosis observed in IL-4-deﬁcient mice was much
less pronounced than that in sIL-13Ralpha2-Fc-treated animals
(Chiaramonte et al., 1999a,b; Fallon et al., 2000)
Both IL-4 and IL-13 predominately induce STAT6 activation in
HSCs. Blockage of STAT6 with siRNA attenuates HSC activation
in vitro (Aoudjehane et al., 2008). After infection with S. man-
soni, STAT6-deﬁcientmice have smaller granulomas anddecreased
amounts of collagen deposition in the liver compared with wild-
type mice (Kaplan et al., 1998). However, a recent study (Liu
et al., 2011) has demonstrated that ERK1/2 pathway rather than
STAT6 in HSCs contributes to IL-13 induction of connective tissue
growth factor, a key mediator in stimulating extracellular matrix
deposition in the liver. In addition, although IL-13 immunostain-
ing correlates with ﬁbrotic stage in patients with HCV infection
and steatohepatitis, pSTAT6 was only detected in 5 out of 120
ﬁbrotic tissues from these patients, suggesting that the pro-ﬁbrotic
effect of IL-13 in human liver diseases is mediated via an STAT6-
independent pathway (Weng et al., 2009). Finally, in lung ﬁbrosis,
two studies showed that STAT6-deﬁcient mice still develop into
ﬁbrosis in two murine models induced by transient ectopic over-
expressionof oncostatinM(Fritz et al., 2011) or by an intratracheal
challenge with live A. fumigatus conidia (Blease et al., 2002). Col-
lectively, although IL-13 plays an important role in promoting liver
ﬁbrogenesis in S.mansoni infection, the role of STAT6 inHSCs and
FIGURE 1 |The effects of cytokines and their downstream STATs in different cell types in liver fibrogenesis.
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liver ﬁbrogenesis seems controversial, which needs to be clariﬁed
by further studies.
CONCLUSIONS AND CLINICAL PERSPECTIVES
In summary, the activation of the JAK–STAT signaling pathways
plays a complex role in controlling liver ﬁbrogenesis. In general,
as shown in Figure 1, STAT1 acts as an anti-ﬁbrotic signaling
molecule via the induction of HSC apoptosis and cell cycle arrest.
STAT3 and STAT5 may also act as anti-ﬁbrotic signaling molecules
via their hepatoprotective functions, thereby preventing injury-
driven liver ﬁbrosis. However, the functions of STAT3 and STAT5
activation in HSCs remain obscure and require further studies.
Although the antiviral effect of STAT2 is well documented, it is
not clear whether or not STAT2 also plays a role in contributing
to the IFN-α/β-mediated anti-ﬁbrotic effects in the liver. Finally,
the biological functions of STAT4 and STAT6 in the pathogen-
esis of liver diseases, including liver ﬁbrogenesis, remain largely
unknown.
Despite extensive research on the functions of STATs in liver
ﬁbrogenesis, the translation of these basic research ﬁndings into
new therapies has been modest. Based on research ﬁndings that
IFN-γ activation of STAT1 is effective in ameliorating liver ﬁbro-
sis in animal models, IFN-γ has been tested in clinical trials for
treating liver ﬁbrosis in patients. It has been reported that IFN-γ
treatment for 9 months does not reduce viral load but improves
ﬁbrosis scores in patients with chronic HBV infection (Weng
et al., 2005; Wu et al., 2011); however, another large double-blind,
placebo-controlled trial showed that IFN-γ therapy was not able
to reverse ﬁbrosis in patients with advanced liver disease (Pock-
ros et al., 2007). The disappointing results from the anti-ﬁbrotic
therapy of IFN-γ in the latter study may be due to the selec-
tion of patients with end-stage of liver disease, poor efﬁcacy, or
to unwanted off-target effects. To overcome this problem, Bansal
et al. (2011) recently developed an engineered, targeted IFN-γ,
in which IFN-γ is conjugated to a cyclic recognizing PDGF-β, a
receptor that is highly upregulated on activated HSCs. Adminis-
tration of this conjugated IFN-γ markedly inhibits liver ﬁbrosis
but does not induce IFN-γ-related side effects in animal models
(Bansal et al., 2011), suggesting that this conjugated IFN-γ is a
promising anti-ﬁbrotic drug for the treatment of liver ﬁbrosis in
patients. Further studies on the anti-ﬁbrotic effect of this targeted
IFN-γ in patients are warranted.
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